Raymond James & Associates Avrobio, Inc. Transaction History

Raymond James & Associates

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$1.29 - $4.04 $19,199 - $60,127	-14,883 Closed	0 $0
Q4 2021 Feb 08, 2022	SELL	$3.45 - $6.05 $1,062 - $1,863	-308 Reduced 2.03%	14,883 $57,000
Q3 2021 Nov 02, 2021	BUY	$5.53 - $9.28 $84,006 - $140,972	15,191 New	15,191 $85,000
Q1 2020 Apr 21, 2020	SELL	$10.08 - $27.21 $114,186 - $308,234	-11,328 Closed	0 $0
Q3 2019 Nov 07, 2019	BUY	$14.12 - $23.44 $159,951 - $265,528	11,328 New	11,328 $160,000

559K

Ticker AVRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,773,900
Description
AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.